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Abstract.
Background: Alzheimer’s disease (AD) is associated with variable cognitive and functional decline, and it is difficult to predict
who will develop the disease and how they will progress.
Objective: This exploratory study aimed to define latent classes from participants in the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database who had similar growth patterns of both cognitive and functional change using Growth Mixture
Modeling (GMM), identify characteristics associated with those trajectories, and develop a decision tree using clinical predictors
to determine which trajectory, as determined by GMM, individuals will most likely follow.
Methods: We used ADNI early mild cognitive impairment (EMCI), late MCI (LMCI), AD dementia, and healthy control
(HC) participants with known amyloid- status and follow-up assessments on the Alzheimer’s Disease Assessment Scale -
Cognitive Subscale or the Functional Activities Questionnaire (FAQ) up to 24 months postbaseline. GMM defined trajectories.
Classification and Regression Tree (CART) used certain baseline variables to predict likely trajectory path.
Results: GMM identified three trajectory classes (C): C1 (n = 162, 13.6%) highest baseline impairment and steepest pattern of
cognitive/functional decline; C3 (n = 819, 68.7%) lowest baseline impairment and minimal change on both; C2 (n = 211, 17.7%)
intermediate pattern, worsening on both, but less steep than C1. C3 had fewer amyloid- or apolipoprotein-E 4 (APOE4) positive
and more healthy controls (HC) or EMCI cases. CART analysis identified two decision nodes using the FAQ to predict likely
class with 82.3% estimated accuracy.
Conclusions: Cognitive/functional change followed three trajectories with greater baseline impairment and amyloid and APOE4
positivity associated with greater progression. FAQ may predict trajectory class.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neu-
rodegenerative disease typically characterized by slow
cognitive and functional decline; however, consider-
able variability in rate of progression makes it hard
to predict an individual’s future course. AD is a
continuum beginning pathologically decades before
symptoms appear (preclinical stage) [1]. Symptoms
progress through an early to late phase of mild cog-
nitive impairment (MCI) and then worsen to include
a more pronounced functional impairment referred to
as dementia. Clinicians would like to provide patients
with a likelihood of progression and how fast it may
occur. Early detection and intervention might delay
cognitive deterioration and/or reduce costs, especially
in someone who could progress quickly. It is also
important to understand disease progression for future
clinical trials.
While historically AD progression has been mod-
eled as a linear process, we now know that progression
is typically slower in early disease stages and then
increases more rapidly as the patient progresses into
dementia [2, 3]. Sona and colleagues reviewed 82 stud-
ies assessing the role that various factors may have
on rapid cognitive decline in AD [4]. In the studies
reviewed, disease progression was modeled using indi-
viduals’ mean cognitive scores that were regressed
on covariates such as diagnosis, age, and education,
to determine their impact on disease progression [4].
These approaches attempt to describe the relationships
among variables with the goal of identifying significant
predictors of outcome. The limitation of these types of
analyses is that they do not allow for subpopulations
with variable rates of progression and they assume that
one trajectory is adequate to describe the whole study
population.
Growth Mixture Modeling (GMM) is a modeling
approach that looks for relationships among individ-
uals’ trajectories with the goal of classifying groups
based on similar growth patterns [5, 6]. This approach
enables identification of unobserved subpopulations
based on similarities in their growth patterns over time
rather than assuming that one trajectory approximates
the whole population. Additionally, GMM allows for
non-linear (e.g., quadratic) progression curves. Sev-
eral studies have used GMM to follow trajectories of
change in cognition and/or functioning in subjects at
various stages of AD. Small and Backman utilized
GMM to follow longitudinal trajectories of cognitive
change as assessed by decline in Mini-Mental State
Examination (MMSE) scores in preclinical AD and
reported that a two-group quadratic model (and not a
linear model) of cognitive decline provided the best
statistical fit to the observed data [7]. Others have used
GMM to follow trajectories of cognitive decline in
cognitively healthy older adults followed for up to 54
months [8], and in Caucasian subjects with possible or
probable AD for up to 13.5 years [9]. Leoutsakos et
al. used parallel-process GMM to model class mem-
bership jointly as a function of both cognitive and
functional decline by assessing change in MMSE and
Clinical Dementia Rating Sum of Boxes (CDR-SB)
scores and reported four distinct latent classes [10].
The objectives of this exploratory study were to
define unobserved subgroups (latent classes) from par-
ticipants in the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database who had similar growth
patterns of both cognitive and functional change using
GMM, and to identify characteristics associated with
those trajectories. We then applied Classification and
Regression Tree (CART) analysis [11] to develop a
decision tree that uses clinical predictors that could be
applied to individuals to determine which trajectory, as
determined by GMM, they will most likely follow.
METHODS
Subjects
Data were obtained in August 2013 from the ADNI
database (http://adni.loni.usc.edu). ADNI recruited
cognitively normal older individuals (healthy control,
HC), and persons with early or late MCI (EMCI,
LMCI) and AD dementia across the U.S. and Canada.
Baseline characteristics of the overall population can
be found in Table 1. Written informed consent was
obtained for participation and approved by the insti-
tutional review board at each participating center.
Detailed diagnostic, inclusion and exclusion criteria
are described on the ADNI website (http://www.adni-
info.org/).
We included all HC, EMCI, LMCI, and AD demen-
tia subjects from ADNI -1, ADNI-GO, and ADNI-2
who had at least one amyloid measurement using
cerebrospinal fluid (CSF) amyloid 1-42 (A42),
[11C] Pittsburgh compound B (PiB) positron emis-
sion tomography (PET) or [18F] florbetapir (FBP)
PET, and at least one post-baseline assessment on
the Alzheimer’s Disease Assessment Scale–Cognitive
Subscale (ADAS-Cog13) or the Functional Activities
Questionnaire (FAQ). Our study defined the base-
line visit as the first amyloid measurement visit, for
which we also used that associated clinical diagnosis.
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Table 1
Baseline demographics and other clinical characteristics by latent class (mean ± SD unless otherwise specified)
Class 1 Class 2 Class 3 Total p-value*
n = 162 n = 211 n = 819 n = 1,192
Age (years) 74.7 ± 8.31 74.4 ± 7.28 72.9 ± 7.16 73.4 ± 7.38 0.0021
Female (%) 59.3% 62.1% 54.8% 56.7% 0.1287
Race (% Caucasian) 97.5% 96.2% 92.3% 93.7% 0.0612
Education (years) 15.7 ± 2.92 15.8 ± 2.92 16.1 ± 2.75 16.0 ± 2.81 0.0968
EVIQ 114.3 ± 8.83 113.7 ± 9.62 117.8 ± 8.24 116.6 ± 8.75 <0.0001
Amyloid Positive† 92.0% 84.4% 48.2% 60.6% <0.0001
APOE 4 carrier 69.1% 64.0% 38.3% 47.1% <0.0001
Diagnosis (%): <0.0001 (By column)
HC (n) 0 2 323 325
% of Column 0.0% 0.9% 39.4% 27.3%
% of Row 0.0% 0.6% 99.4% 100%
EMCI (n) 5 29 245 279
% of Column 3.1% 13.7% 29.9% 23.4%
% of Row 1.8% 10.4% 87.8% 100%
LMCI (n) 29 105 238 372
% of Column 17.9% 49.8% 29.1% 31.2%
% of Row 7.8% 28.2% 64.0% 100%
AD (n) 128 75 13 216
% of Column 79.0% 35.5% 1.6% 18.1%
% of Row 59.3% 34.7% 6.0% 100%
Medical History
Alcohol Abuse 8.0% 3.3% 3.9% 4.4% 0.0474
Smoking 40.1% 37.4% 38.7% 38.7% 0.8699
Cardiovascular disease 71% 64% 67.9% 67.6% 0.3433
Endocrine disease 42.6% 42.7% 40.2% 40.9% 0.7261
ADAS-Cog13 29.8 ± 9.55 23.5 ± 7.39 12.5 ± 6.10 16.8 ± 9.54 <0.0001
FAQ 16.1 ± 6.15 6.5 ± 4.41 1.2 ± 2.26 4.1 ± 6.21 <0.0001
Animal Category Fluency 12.0 ± 4.95 15.0 ± 5.10 19.0 ± 5.33 17.4 ± 5.85 <0.0001
CDR-SB 4.9 ± 2.08 2.6 ± 1.25 0.8 ± 0.85 1.7 ± 1.86 <0.0001
Wechsler LM II 1.7 ± 2.32 3.3 ± 3.30 9.2 ± 4.65 7.1 ± 5.20 <0.0001
MMSE 23.5 ± 3.11 25.8 ± 2.44 28.3 ± 1.73 27.2 ± 2.74 <0.0001
MoCA 17.3 ± 4.73 20.3 ± 3.32 24.5 ± 2.89 23.1 ± 4.08 <0.0001
Trail Making Test Part A 68.7 ± 35.91 48.8 ± 26.62 36.7 ± 14.40 43.1 ± 23.70 <0.0001
Trail Making Test Part B 200.8 ± 84.99 160.7 ± 80.08 96.3 ± 52.76 120.9 ± 74.00 <0.0001
NPI-Q 4.4 ± 4.62 2.9 ± 3.50 1.2 ± 1.99 2.0 ± 3.07 <0.0001
GDS Short Form 1.8 ± 1.76 1.7 ± 1.40 1.4 ± 1.47 1.5 ± 1.51 0.0007
Data are presented as mean ± SD unless indicated otherwise. APOE, apolipoprotein E; AD, Alzheimer’s disease; ADAS-Cog13, Alzheimer’s
Disease Assessment Scale-Cognitive Subscale, 13-item version; CDR-SB, Clinical Dementia Rating Sum of Boxes; EMCI, early mild cognitive
impairment; EVIQ, Estimated Verbal Intelligence Quotient; FAQ, Functional Activities Questionnaire; GDS, Geriatric Depression Scale; HC,
healthy controls; LM, Logical Memory; LMCI, late mild cognitive impairment; MMSE, Mini-Mental State Examination; MoCA, Montreal
Cognitive Assessment; NPI-Q, Neuropsychiatric Inventory-Questionnaire. ∗p-values were from likelihood ratio test in multinomial logit model
for categorical measures and from analysis of variance corrected for uncertainty for continuous variables. Uncertainty in latent class assignment
is taken into consideration, using a three-step manual calculation as in Asparouhov & Muthe´n [15]. †31 cases had discrepant amyloid test results
(20 out of 31 discrepant cases were CSF positive but FBP-PET negative).
All EMCI and LMCI subjects were required to have
MMSE scores between 24–30 (inclusive), a subjec-
tive memory concern reported by subject, informant,
or clinician, absence of significant levels of impair-
ment in other cognitive domains, essentially preserved
activities of daily living, and an absence of dementia.
EMCI and LMCI were distinguished from each other
using education adjusted scores on delayed recall of
one paragraph from Wechsler Memory Scale-Revised
Logical Memory II (WMS-LMII) (EMCI: ≥16 years
of education: score range 9–11; 8–15 years: 5–9; 0–7
years: 3–6; LMCI: ≥16 years: ≤8; 8–15 years: ≤4;
0–7 years: ≤2). For some subjects the first amyloid
measurement (our study baseline) occurred after ini-
tial enrollment in ADNI, and those who converted
to MCI were not designated as EMCI and LMCI at
post-entry follow-up visits. For those MCI subjects,
we applied the WMS-LMII education-adjusted score
ranges from the ADNI-2 protocol to separate them into
EMCI and LCMI groups. Inclusion criteria for AD sub-
jects were MMSE scores between 20–26 (inclusive),
a global Clinical Dementia Rating Scale score of 0.5
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or 1.0, and meeting National Institute of Neurologi-
cal and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Associa-
tion (NINCDS/ADRDA) criteria for probable AD. A
specific functional scale was not mandated as part of
the clinical diagnosis.
Amyloid positive status was defined according
to either PiB-PET composite standard uptake value
ratio (SUVR) mean across five regions of interest
(ROI) (anterior cingulate, frontal, lateral temporal, pre-
cuneus, and parietal cortices) of >1.6 normalized to
the cerebellar cortex [12], FBP-PET composite SUVR
of ≥1.1 mean across six ROIs (anterior and posterior
cingulate, precuneus, frontal, temporal, and parietal
cortices) using the whole cerebellum reference region
[13], or CSF A42 ≤192 pg/ml [14]. When a subject
had more than one amyloid measure at baseline, the
amyloid status was considered to be positive if at least
one measure was positive.
The ADAS-Cog13, a 13-item cognitive test (score
range 0 [normal] to 85 [impaired]), and the FAQ, an
informant-rated, 10-item functional scale (score range
0 [no impairment] to 30 [dependent]), were assessed
at baseline, 6-, 12-, and 24-month visits.
Demographic data, apolipoprotein E 4 (APOE4)
status (presence or not of at least one 4 allele), FAQ,
MMSE, Montreal Cognitive Assessment (MoCA),
WMS-LMII, CDR-SB, Trail Making Test (TMT) Parts
A and B, Geriatric Depression Scale (GDS) short form,
and Neuropsychiatric Inventory (NPI)-Q scores were
also documented from our study baseline visit.
Statistical analyses
GMM jointly modeled ADAS-Cog13 and FAQ
scores to identify unobserved subpopulations based
on similarity in trajectories, regardless of diagnosis
or other clinical characteristics [5, 6]. The optimal
number of subpopulations was determined by eval-
uating k (starting from 2) classes versus k-1 classes
sequentially, until adding an additional class no longer
statistically significantly improved fit through Lo-
Mendell-Rubin-Adjusted Likelihood Ratio test. The
mean structure (i.e., linear, quadratic, cubic, etc.) in
GMM was determined by selecting the best-fitting
model as defined by the largest Entropy and lowest
Bayesian information criterion value.
Baseline characteristics were compared among the
latent classes, including diagnosis, demographics,
comorbidities, other clinical and cognitive measures,
and amyloid and APOE4 status, with a likelihood ratio
test in multinomial logit model for categorical char-
acteristics, and analysis of variance for continuous
measures. Uncertain class assignment was taken into
consideration, using the three-step approach proposed
in Asparouhov and Muthen [15].
CART [11] evaluated baseline variables to deter-
mine those that best predicted GMM most likely class
membership. The model included gender, amyloid
status, history of alcohol, smoking, cardiovascular dis-
ease, endocrine disease, education, age, as well as
animal category fluency, FAQ, MMSE, MoCA, and
NPI-Q scores. We built the classification tree using all
data. Prediction accuracy was obtained through 10-fold
cross-validation.
GMM was done in Mplus 7.1. CART was imple-
mented using rpart package in R 15.3. And SAS 9.2
was used for all other analyses. Significance level of
0.05 was used when applicable.
RESULTS
The total dataset included 325 HC, 279 EMCI, 372
LMCI, and 216 AD dementia subjects. The average
length of follow-up for the FAQ was 16.3 months
(SD ± 7.1) and for the ADAS-Cog13 was 16.2 (±7.1).
Overall, 60% subjects were considered amyloid posi-
tive with amyloid positivity increasing with advanced
disease stage (HC 35.1%, EMCI 51.3%, LMCI 71.8%,
AD 91.7%). There were 31 cases that had discrepant
amyloid results between CSF and FBP-PET (20 of the
31 discrepant cases were CSF positive but FBP-PET
negative, and the opposite was true for the remaining
11 cases).
Table 2 shows a number of GMM models from
which the final model was selected. The final model
identified three quadratic trajectories across all sub-
jects for cognitive/functional change as measured by
the ADAS-Cog13 and FAQ bivariate analysis. While
the graphs in Fig. 1 illustrate trajectories using mean
values of individuals assigned to each class for each
scale separately, GMM took both cognition and func-
tion into consideration when determining the classes.
Additionally, Fig. 2 illustrates spaghetti plots of indi-
viduals’ trajectories in each class, overlayed with the
fitted mean trajectory of that class.
Class 1 (n = 162, 13.6%) had the highest baseline
FAQ and ADAS-Cog13 scores and steepest pattern of
cognitive and functional worsening of all classes. In
contrast, Class 3 (n = 819, 68.7%) had the lowest base-
line FAQ and ADAS-Cog13 scores and minimal change
on both over time. Class 2 (n = 211, 17.7%) had an
intermediate pattern with baseline FAQ and ADAS-
Cog13 scores that were more impaired than Class 3 but
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Table 2
GMM adjustment indices for 2 to 4 classes
Number of Classes Growth Structure AIC BIC p-Value LMR-LRT Entropy n (%) of smallest class
2 Linear 43178.7 43321.0 <0.0001 0.943 217 (18.2%)
Quadratic 43181.7 43369.8 <0.0001 0.946 219 (18.4%)
3 Linear 42868.6 43041.5 0.0081 0.912 162 (13.6%)
Quadratic 42802.1 43030.8 0.0329 0.917 162 (13.6%)
4 Linear 42794.9 42977.9 0.3796 0.928 79 (6.6%)
Quadratic 42495.6 42765.1 0.0819 0.944 64 (5.4%)
AIC, Akaike Information Criteria; BIC, Bayesian Information Criteria; LMR-LRL, Lo-Mendell-Rubin - Likelihood Ratio Test.
Fig. 1. Three trajectories (latent classes) are graphed for the FAQ (left) and ADAS-Cog13 (right) when jointly modeled by GMM.
less than Class 1, and worsening on both scales that
was slower than for Class 1.
Table 1 shows baseline demographics by latent
class. Significant differences were observed among
the three classes across most variables including age
(p = 0.0021), APOE4 status (p < 0.0001), amyloid sta-
tus (p < 0.0001), diagnosis (p < 0.0001), alcohol abuse
(p = 0.0474), and all clinical and cognitive measures
(p < 0.0001 except GDS p = 0.0007). No significant
differences were observed for gender, education, or
comorbidities of smoking, cardiovascular disease, or
endocrine disease. On average, Class 1 subjects were
older and more likely amyloid (92%) or APOE4
(69.1%) positive. The majority of Class 1 was diag-
nosed with AD dementia (79%) or LMCI (17.9%).
This group showed the greatest amount of impair-
ment across measures of cognition and function and
the greatest neuropsychiatric symptom severity.
In contrast, Class 3 subjects were younger and less
likely to be amyloid (48.2%) or APOE4 (38.3%) pos-
itive. Class 3 included HCs (39%) or were diagnosed
with EMCI (29.9%) or LMCI (29.1%), and showed the
least amount of impairment across all measures of cog-
nition and function, and the lowest neuropsychiatric
symptom severity.
Class 2 subjects were HCs (0.9%) or diagnosed
with EMCI (13.7%), LMCI (49.8%), or AD demen-
tia (35.5%). Subjects were close in age to Class 1, and
a higher percentage than Class 3 was amyloid (84.4%)
or APOE4 (64%) positive but slightly less than Class 1.
Baseline scores on cognitive, functional, and neuropsy-
chiatric scales were intermediate between Classes 1
and 3.
Figure 3 shows FAQ or ADAS-Cog13 mean scores
by diagnostic group graphed adjacent to each class’s
trajectory line. As expected, the arrays for mean score
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Fig. 2. Individual trajectories graphed for each subject within each latent class are shown for the FAQ (top) and the ADAS-Cog13 (bottom)
when jointly modeled by GMM. Class trajectories (from Fig. 1) are shown in color.
lines were ordered according to level of impairment of
each diagnostic group and either above or below the
latent class line.
CART analysis identified the FAQ as the input vari-
able most predictive of latent classes found in GMM
with two decision nodes that separated subjects into
their most likely class at an estimated prediction accu-
racy of 82.3% (SD 1.11%) (Fig. 4). The first node
partitioned Class 3 if the FAQ score was <5. The
remaining subjects were split at the second node into
Class 2 if the FAQ was <14, and into Class 1 if the FAQ
was ≥14.
DISCUSSION
We approached the topic of clinical trajectories by
using a person-centered modeling approach (GMM)
in contrast to most other reports that use variable-
centered approaches [4]. This enabled us to discern
unobserved subpopulations based on similarities in
their growth patterns over time rather than to assume
that one trajectory approximates the whole population
or to specify subgroups based on one or more variables.
We found that the combination of cognitive and func-
tional change over a 24-month period followed three
distinct trajectories, represented by one class with the
lowest baseline cognitive and functional impairment
and virtually no change (Class 3) and two classes that
both progressed but were separated by their degree of
baseline impairment. Additionally, there were some
clinical characteristics that differed across the classes,
such as diagnosis, APOE4, and amyloid status. Our
study included cases ranging from HC through AD
dementia as diagnosed in the ADNI cohort, while other
studies may not have addressed this whole spectrum.
Further, we only selected ADNI cases where amy-
loid status was known, whereas most prior reports
do not have the benefit of knowing amyloid status.
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Fig. 3. Trajectories are graphed to reveal diagnostic subgroups for Classes 1, 2, and 3 for the FAQ (top) and the ADAS-Cog13 (bottom) when
jointly modeled by GMM. Class trajectories (from Fig. 1) are shown in color.
Fig. 4. Classification and Regression Tree (CART) analysis of multiple variables selected categorical cutoffs on the FAQ as the best determinant
to predict most likely class membership attributable to the original GMM classifications. CART predication accuracy was 82.3% as compared to
the original GMM classes. Diagnostic group identity of subjects resulting from the CART attribution to the GMM classes is listed in the colored
boxes and the distribution of the same subjects to specific classes in the original GMM classes is listed below the colored boxes for each Class.
Finally, GMM allowed quadratic in addition to linear
trajectories.
Our study found three trajectories of cognitive and
functional change. Class 1 had the highest base-
line FAQ and ADAS-Cog13 scores and the steepest
pattern of cognitive and functional worsening. In
contrast, Class 3, the largest group, had the lowest
baseline FAQ and ADAS-Cog13 scores and minimal
change on both scales. Not surprisingly, its constituents
had diagnoses suggesting earlier stages of disease
278 H. Hochstetler et al. / AD Cognitive and Functional Trajectories
(%HCs>EMCI = LMCI). It is notable that almost half
the individuals in this class of non-progressors were
amyloid positive and we may have seen this class
progress with a longer follow-up period. Class 2 had
an intermediate pattern with baseline FAQ and ADAS-
Cog13 scores that were more impaired than Class 3 but
less than Class 1, and worsening on both scales, but
less steep than for Class 1. Consistent with this pat-
tern, Class 2 constituents, by diagnosis (%LMCI>AD
dementia>EMCI), reflected less overall disease sever-
ity than in Class 1 (%AD dementia>LMCI>EMCI).
A longer follow-up period could confirm whether the
trajectory for Class 2 would eventually look like that
for Class 1 as patients become more impaired. It is
important to note that we did not look at the relation-
ship between cognitive and functional decline because
GMM was a bivariate analysis, nor do we know how the
scales perform relative to each other in a psychometric
fashion.
Previous studies have described trajectories of
change in cognition and behavior in subjects with MCI
or AD dementia. Xie and colleagues [16] used group-
based trajectory analysis to identify distinct cognitive
change patterns among a cohort of 187 MCI patients
from two geriatric outpatient clinics over a course of
up to 3.5 years. Five trajectories were identified and
labeled based on their baseline MMSE score. Their
two least cognitively impaired groups (MMSE of 27
and 29) had a stable course, which is consistent with
our findings for Class 3.
Other studies with longer patient follow-up periods
(up to 13.5 years) [9, 10] found that cognitive func-
tion, as measured by the MMSE, eventually declined
to very low levels in almost all of the trajectories. In
contrast, studies that delineate a group with a stable
cognitive trajectory [2] or “nonprogression” in cogni-
tion and function (like ours) have the shortest follow-up
periods (2 to 3.5 years). Wilkosz and colleagues [9]
used latent class modeling and found six trajectories
of cognitive and behavioral decline in a cohort of
201 Caucasian subjects with possible or probable AD
dementia followed for up to 13.5 years. The concomi-
tant variables included in the best latent class trajectory
model were initial MMSE and age. Also, two of our
co-authors (JSL and CGL) completed an analysis to
identify classes of progression trajectories in incident
AD dementia cases from the Cache County Dementia
Progression Study in up to 8 years of follow-up, and
to identify baseline predictors of membership for each
group [10]. Using bivariate GMM based on MMSE and
CDR-SB scores, those authors identified four latent
classes. Class 1 was the largest (72%) and had the
slowest progression as compared to the other three
classes with more rapid worsening. In a multivari-
ate model, only MMSE was a statistically significant
predictor of likely class membership. However, these
two studies only included subjects with dementia.
Our study also included HC and EMCI subjects who
progress more gradually over many years [17]. Overall,
our findings are consistent with reports that the course
of cognitive impairment in clinically diagnosed AD is
variable, starts slow and progressively increases over
time [2, 17].
A recent review of 82 studies that reported at least
one factor associated with rate of progression for an
AD patient population considered an extensive list of
potential factors such as age, age of onset, gender, edu-
cation, family history of dementia, MMSE and CDR
scale baseline scores, comorbidities, APOE genotype,
and cholinesterase inhibitor use [4]. Study results were
often contradictory, and no reliable conclusions regard-
ing factors possibly associated with rapid cognitive
decline could be made; however, a trend was found for
younger, more educated and/or more impaired patients.
The more rapid decline in the higher educated is con-
sistent with the hypothesis that higher cognitive reserve
protects from early clinical manifestation of AD, but
later patients deteriorate more rapidly as the disease
progresses.
We found that class membership was associated
with baseline age, APOE4 and amyloid status, diagno-
sis, and all cognitive, functional, and neuropsychiatric
scores. Subjects that progressed were more often
APOE4 or amyloid positive, older in age, and later
in their disease stage. A number of studies, but not all
[18], report that younger subjects have a more rapid
decline in cognition compared to older subjects, as
reviewed by Sona et al. [4]. However, we found an
opposite association for age with class membership
where subjects in Class 1 with the steepest progression
were older than in Class 3, though we did not control
for time from disease onset or disease severity, and
AD and HC groups were age-matched, while EMCI
and LMCI groups were younger on average. This find-
ing may be driven by the fact that amyloid portends
poorer outcome, especially when combined with other
pathologies that increase with aging. Our findings are
consistent with a number, but not all, of other studies
that report greater cognitive decline in subjects with
worse baseline cognitive impairment [3, 4, 19, 20].
APOE4 positivity is associated with a greater decline in
function [21] and cognition [22, 23], although this rela-
tionship has not been observed consistently [24–27].
Possible explanations have focused on linear versus
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non-linear statistical models [22], or different AD clin-
ical populations [23]. Our study results are consistent
with a number of studies showing that amyloid positiv-
ity is associated with worse baseline scores and disease
progression [1, 28–33]. Additionally, a faster decline
in cognition is reportedly associated with increased
neuropsychiatric symptom severity including agitation
and wandering [34], hallucinations and delusions [35],
and depressive symptoms [36]. Our results showed a
higher NPI-Q score was associated with faster pro-
gression, but the overall severity of neuropsychiatric
symptoms was low in our sample.
We did not find class membership to be asso-
ciated with gender, education, or comorbidities of
smoking, cardiovascular disease, or endocrine disease,
although there is other evidence that vascular risk
factors are associated with greater functional and cog-
nitive decline [26, 37, 38]. Regan and colleagues [39]
note though these risk factors may contribute to AD
initially, they are not part of the underlying disease
process. Alcohol abuse showed a significant difference
among the trajectory classes in our analysis, but the
percentage of patients reporting alcohol abuse was rel-
atively low among the groups (range: 3.3% to 8%),
making this finding less reliable. Those with higher
cognitive reserve (more years of education) diagnosed
with AD show an initial delay in symptom expression,
followed by a more rapid rate of cognitive decline [4].
In the current study, education did not differ among the
three classes, though most subjects in the ADNI cohort
have a high level of education, limiting the ability to
study this factor.
CART analysis can uncover complex interactions
among predictors of trajectory class membership
which could be difficult to identify using traditional
multivariate techniques [11]. The result is a decision
tree with a series of if-then scenarios to best allo-
cate individuals to a particular class when applying the
variable cutoff values that produced the best fit. This
provides a straightforward approach to apply clinical
predictors. The CART analysis identified two decision
nodes, both based on FAQ results, to predict which sub-
jects most likely belong to the GMM classes. While
the ADAS-Cog13 and FAQ results jointly defined
the original GMM classes, we chose to exclude the
ADAS-Cog13 because it is utilized in research and
not available to a clinician. However, we ran a sep-
arate CART analysis that included the ADAS-Cog and
the FAQ remained the main differentiator. It is note-
worthy that baseline cognitive variables or amyloid
status were not better predictors of GMM member-
ship. The FAQ is a functional measure that includes
instrumental activities of daily living, such as prepar-
ing balanced meals and managing personal finances,
and can be easily administered in a clinician office.
Perhaps the FAQ cutoff values of 5 and 14, as identified
through CART analysis, can facilitate identification of
who will progress in other patient populations. These
findings may extend the initial report suggesting a cut
point of ≥9 (“dependent” or a score of 3 in three or
more activities) to indicate impaired function consis-
tent with dementia [40]. However, CART analyses are
exploratory for generating hypotheses that need further
testing.
There are some limitations to this study that should
be taken into consideration. When determining amy-
loid status, we used CSF A42, PiB-PET, or FBP-PET
results. However, 31 cases had discrepant amyloid
results (20 of 31 discrepant cases were CSF posi-
tive but FBP-PET negative). Possible reasons for this
include the fact that CSF measures soluble A and
PET measures insoluble deposited amyloid plaque.
Additionally, there is variability across CSF assays and
laboratories, with no standardized cutoff for amyloid
positivity [41]. ADNI attempts to control for this vari-
ability by using a centralized laboratory for the CSF
assays but CSF A specimens must be handled care-
fully and there could be site variability in this handling.
For our analyses, we used the latest ADNI cutoffs for
CSF amyloid positivity [14]. Another possible cause
for the amyloid test discordance could be false negative
scan results, which have been observed with FBP-PET
[42]. CART uses most likely class membership, and
cannot accommodate the fact that a subject could be
in another class with smaller probability. Although our
sample size of 1,192 was relatively large, the follow-
up period of up to two years (mean about 16 months)
may not be long enough to see progression, especially
earlier in the disease spectrum. In addition, the rel-
atively low incidence of comorbidities, limited racial
representation and high years of education in the ADNI
population may limit generalizability of these results.
We included HCs in the analyses as some are still at risk
for AD and could be transitional toward impairment
and indeed, some were amyloid positive (35%).
Our findings make a unique contribution to the litera-
ture on longitudinal change in older persons, including
those clinically diagnosed with MCI and AD demen-
tia and may help inform clinicians and patients when
amyloid biomarker testing is not available. Moreover,
patients with MCI were further subdivided into EMCI
and LMCI to better capture how those categorical des-
ignations populated the three latent classes. Our sample
was larger than most prior reports and the amyloid
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status of patients was known. Third, we looked at
changes in both cognition and function. Lastly, we
used CART analysis to develop a decision tree, and
identified two decision nodes based on the FAQ that
separated patients along the three latent classes. These
decision nodes may further the understanding of the
FAQ scale cutoff values in relation to severity of
impairment.
In summary, the combination of cognitive and func-
tional change over a 24-month period followed three
distinct trajectories where positive APOE4 and amy-
loid status were more associated with a subpopulation
that had greater decline over time (64%–69% and
84%–92%, respectively). The FAQ score may help to
predict trajectory. This type of information could be
shared by the physician to help patients and families
plan for the future. However, our results are exploratory
and should be confirmed in other populations with
longer term follow-up.
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